Oncology Consults: Immunotherapy for the Treatment of NSCLC
PROGRAM DESCRIPTION Lung cancer is the leading cause of cancer-related mortality in the world, and approximately 85% of all lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC). ...
Lung cancer is the leading cause of cancer-related mortality in the world, and approximately 85% of all lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC). Of those with NSCLC, approximately 40% present with advanced unresectable disease. For decades, chemotherapy has been the standard of care for patients without mutations who are sensitive to targeted therapy. However, chemotherapy only provides limited therapy with a limited safety profile. Immunotherapy is a new approach to treating patients with NSCLC. Immune checkpoint blockade increases antitumor immunity by blocking down-regulators of immunity, such as programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1). Several clinical trials have consistently demonstrated superior efficacy of several immune checkpoint-directed antibodies (ie, nivolumab, pembrolizumab, and atezolizumab) in treating patients with advanced NSCLC. This case activity will provide clinicians who treat and manage patients with advanced stage NSCLC with the most up-to-date information on the most effective treatment options, specifically with immunotherapies.
After participating in this activity, the participant will demonstrate the ability to:OUTLINE essential concepts of adaptive immune responses with regards to NSCLC immunotherapies.IDENTIFY the efficacy and safety of novel and investigational NSCLC immunotherapies.INCORPORATE novel NSCLC immunotherapies into treatment plans based on treatment algorithms and recommendations.The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.
I'm interested in this
Share with others
Write the first review
Share with others